Extracellular matrix as target for antitumor therapy

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 1387-1398

  Harisi, Revekka ^a   Jeney, Andras ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Heparan sulfate proteoglycan; Three dimensional ECM; Tumor microenvironment; Tumor progression

Indexed keywords

4 BENZYL 3 HEXADECANOYL 5 HYDROXYMETHYLTETRONIC ACID; 5 HEXYL 2 DEOXYURIDINE; ABITUZUMAB; AGRIN; ALPHAVBETA5 INTEGRIN; ANTINEOPLASTIC AGENT; BATIMASTAT; BORRELIDIN; CILENGITIDE; COLLAGEN; CYTOTOXIC AGENT; DOXORUBICIN; GLYPICAN; HEPARANASE; HEPARANASE INHIBITOR; MATRIX METALLOPROTEINASE; MUPARFOSTAT; OLIGOMANNURARATE SULFATE; OROXYLIN A; PACLITAXEL; PERLECAN; PG 545; PROTEOGLYCAN; RK 682; S 247; SALVICINE; SYNDECAN; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDOLIZUMAB;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; COLON TUMOR; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROSARCOMA; HUMAN; LUNG METASTASIS; MELANOMA; METASTASIS; METASTASIS INHIBITION; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 84934282532     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S48883     Document Type: Article

References (103)

1. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395-406.
2. Langlois B, Saupe F, Rupp T, et al. AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients. Oncotarget. 2014;5(21):10529-10545.
3. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998;67:609-652.
4. Ali MY, Chuang CY, Saif MT. Reprogramming cellular phenotype by soft collagen gels. Soft Matter. 2014;10(44):8829-8837.
5. Harisi R, Dudás J, Timár F, et al. Invasive growth and topoisomerase-switch induced by tumorous extracellular matrix in osteosarcoma cell culture. Cell Biol Int. 2005;29(11):959-967.
6. Glentis A, Gurchenkov V, Matic Vignjevic D. Assembly, heterogeneity, and breaching of the basement membranes. Cell Adh Migr. 2014;8(3): 236-245.
7. Triulzi T, Casalini P, Sandri M, et al. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS One. 2013;8(2): e56761.
8. Naba A, Clauser KR, Whittaker CA, Carr SA, Tanabe KK, Hynes RO. Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer. 2014;14:518.
9. Bergamaschi A, Tagliabue E, Sørlie T, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008;214(3):357-367.
10. Adamson IY, Young L, Bakowska J. Enhanced alveolar type II cell growth on a pulmonary extracellular matrix over fibroblasts. Am J Physiol. 1997;272(3 Pt 1):L413-L417.
11. Vlodavsky I, Lui GM, Gospodarowicz D. Morphological appearance, growth behavior and migratory activity of human tumor cells maintained on extracellular matrix versus plastic. Cell. 1980;19(3):607-616.
12. Niedbala MJ, Crickard K, Bernacki RJ. Adhesion, growth and morphology of human mesothelial cells on extracellular matrix. J Cell Sci. 1986;85:133-147.
13. Pogány G, Timár F, Oláh J, et al. Role of the basement membrane in tumor cell dormancy and cytotoxic resistance. Oncology. 2001;60(3):274-281.
14. Harisi R, Dudás J, Tímár F, et al. Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix. Anticancer Res. 2005;25(2A):805-813.
15. Harisi R, Dudas J, Nagy-Olah J, Timar F, Szendroi M, Jeney A. Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 function. Cancer Biol Ther. 2007;6(8):1240-1246.
16. Larsen AK, Skladanowski A, Bojanowski K. The roles of DNA topoisomerase II during the cell cycle. Prog Cell Cycle Res. 1996;2:229-239.
17. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710-1715.
18. He CJ, Striker LJ, Tsokos M, Yang CW, Peten EP, Striker GE. Relationships between mesangial cell proliferation and types I and IV collagen mRNA levels in vitro. Am J Physiol. 1995;269(3 Pt 1):C554-C562.
19. Williams DF, Burke JM. Modulation of growth in retina-derived cells by extracellular matrices. Invest Ophthalmol Vis Sci. 1990;31(9):1717-1723.
20. Rutka JT. The K.G. McKenzie award lecture - 1986. Effects of extracellular matrix proteins on the growth and differentiation of an anaplastic glioma cell line. Can J Neurol Sci. 1986;13(4):301-306.
21. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1(2):149-153.
22. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature. 2001;411(6835):375-379.
23. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001;1(1):46-54.
24. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer. 2002;2(7):521-528.
25. Thorns V, Walter GF, Thorns C. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res. 2003;23(5A):3937-3944.
26. Friedl P, Noble PB, Walton PA, et al. Migration of coordinated cell clusters in mesenchymal and epithelial cancer explants in vitro. Cancer Res. 1995;55(20):4557-4560.
27. Hegerfeldt Y, Tusch M, Bröcker EB, Friedl P. Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. Cancer Res. 2002;62(7):2125-2130.
28. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5)362-374.
29. Wolf K, Wu YI, Liu Y, et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol. 2007;9(8):893-904.
30. Friedl P, Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res. 2008;68(18):7247-7249.
31. Friedl P, Wolf K. Proteolytic interstitial cell migration: a five-step process. Cancer Metastasis Rev. 2009;28(1-2):129-135.
32. Harisi R, Kenessey I, Olah JN, et al. Differential inhibition of single and cluster type tumor cell migration. Anticancer Res. 2009;29(8):2981-2985.
33. Jeney A, Kenessey I, Timár F, et al. [Study of drugs against neoplastic metastasis]. Magy Onkol. 2006;50(2):93-100. Hungarian.
34. Arboleda MJ, Lyons JF, Kabbinavar FF, et al. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003;63(1):196-206.
35. Tauro M, McGuire J, Lynch CC. New approaches to selectively target cancer-associated matrix metalloproteinase activity. Cancer Metastasis Rev. 2014;33(4):1043-1057.
36. Stetler-Stevenson WG, Gavil NV. Normalization of the tumor microenvironment: evidence for tissue inhibitor of metalloproteinase-2 as a cancer therapeutic. Connect Tissue Res. 2014;55(1):13-19.
37. Lu N, Ling Y, Gao Y, et al. Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med (Maywood). 2008;233(8):1013-1020.
38. Lu Z, Lu N, Li C, et al. Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett. 2012;209(3):211-220.
39. Saha S, Lo PK, Duan X, Chen H, Wang Q. Breast tumour initiating cell fate is regulated by microenvironmental cues from an extracellular matrix. Integr Biol (Camb). 2012;4(8):897-904.
40. Steelman LS, Chappell WH, Abrams SL, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 2011;3(3):192-222.
41. Provenzano PP, Inman DR, Eliceiri KW, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008;6:11.
42. Liang X, Osman TA, Sapkota D, et al. Rapid adherence to collagen IV enriches for tumour initiating cells in oral cancer. Eur J Cancer. 2014;50(18):3262-3270.
43. Han J, Ohno N, Pasco S, Monboisse JC, Borel JP, Kefalides NA. A cell binding domain from the alpha3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem. 1997;272(33):20395-20401.
44. Sudan S, Rupasinghe HP. Flavonoid-enriched apple fraction AF4 induces cell cycle arrest, DNA topoisomerase II inhibition, and apoptosis in human liver cancer HepG2 cells. Nutr Cancer. 2014;66(7):1237-1246.
45. De Nictolis M, Garbisa S, Lucarini G, et al. 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study. Int J Gynecol Pathol. 1996;15(2):102-109.
46. Shapiro PS, Whalen AM, Tolwinski NS, et al. Extracellular signal-regulated kinase activates topoisomerase I alpha through a mechanism independent of phosphorylation. Mol Cell Biol. 1999;19(5):3551-3560.
47. Anbalagan M, Rao AJ. Collagen IV-mediated signalling is involved in progenitor Leydig cell proliferation. Reprod Biomed Online. 2004;9(4):391-403.
48. Schambony A, Kunz M, Gradl D. Cross-regulation of Wnt signaling and cell adhesion. Differentiation. 2004;72(7):307-318.
49. Pal S, Moulik S, Dutta A, Chatterjee A. Extracellular matrix protein laminin induces matrix metalloproteinase-9 in human breast cancer cell line mcf-7. Cancer Microenviron. 2014;7(1-2):71-78.
50. Kramer RH, Bensch KG, Wong J. Invasion of reconstituted basement membrane matrix by metastatic human tumor cells. Cancer Res. 1986;46(4 Pt 2):1980-1989.
51. Schifferli KP, Henrich CJ. Analysis of integrin expression and function in HT1080 cells using inhibitory anti-integrin antibodies. Focus. 1996;18:13-15.
52. Noël AC, Callé A, Emonard HP, et al. Invasion of reconstituted basement membrane matrix is not correlated to the malignant metastatic cell phenotype. Cancer Res. 1991;51(1):405-414.
53. Kawaguchi S, Uede T. Distribution of integrins and their matrix ligands in osteogenic sarcomas. J Orthop Res. 1993;11(3):386-395.
54. Christensen L. The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. APMIS Suppl. 1992;26:1-39.
55. Assoian RK, Marcantonio EE. The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J Clin Invest. 1997;100(11 Suppl):S15-S18.
56. Hughes PE, Renshaw MW, Pfaf M, et al. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell. 1997;88(4):521-530.
57. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 1999;147(1):89-104.
58. Kleinman HK, McGarvey MJ, Liotta LA, Robey PG, Tryggvason K, Martin GR. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry. 1982;21(24):6188-6193.
59. Timpl R, Fujiwara S, Dziadek M, et al. Laminin, proteoglycan, nidogen, and collagen IV: structural models and molecular interactions. In: Porter R, Whelan J, editors. Basement Membranes and Movement. London: Pitman; 1984:25-74.
60. Liu AY, Zheng H, Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol. 2014;37:150-156.
61. Kovalszky I, Hjerpe A, Dobra K. Nuclear translocation of heparan sulfate proteoglycans and their functional significance. Biochim Biophys Acta. 2014;1840(8):2491-2497.
62. Kovalszky I, Dudás J, Oláh-Nagy J, et al. Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Mol Cell Biochem. 1998;183(1-2):11-23.
63. Suhovskih AV, Mostovich LA, Kunin IS, et al. Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN Oncol. 2013;2013:680136.
64. Mishra M, Chandavarkar V, Naik VV, Kale AD. An immunohistochemical study of basement membrane heparan sulfate proteoglycan (perlecan) in oral epithelial dysplasia and squamous cell carcinoma. J Oral Maxillofac Pathol. 2013;17(1):31-35.
65. Mathiak M, Yenisey C, Grant DS, Sharma B, Iozzo RV. A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells. Cancer Res. 1997;57(11):2130-2136.
66. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998;102(8):1599-1608.
67. Merz DC, Alves G, Kawano T, Zheng H, Culotti JG. UNC-52/perlecan affects gonadal leader cell migrations in C. Elegans hermaphrodites through alterations in growth factor signaling. Dev Biol. 2003;256(1):173-186.
68. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005;5(7):526-542.
69. Harisi R, Dudás J, Pogány G, et al. Repopulation of osteosarcoma cells after treatment with doxorubicin in the presence of extracellular matrix biopolymers. Cancer Chemother Pharmacol. 2006;58(3):334-342.
70. Sancéau J, Truchet S, Bauvois B. Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J Biol Chem. 2003;278(38):36537-36546.
71. Hsiang YH, Wu Hy, Liu LF. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res. 1998;48(11):3230-3235.
72. Ludvíková M, Holubec L Jr, Ryska A, Topolcan O. Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-a immunostaining. Anticancer Res. 2005;25(3A):1835-1840.
73. Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med. 2009;206(3):691-705.
74. Rapraeger AC. Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis. FEBS J. 2013;280(10):2207-2215.
75. Baghy K, Horváth Z, Regős E, et al. Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis. FEBS J. 2013;280(10):2150-2164.
76. Liang S, Xu JF, Cao WJ, Li HP, Hu CP. Human decorin regulates proliferation and migration of human lung cancer A549 cells. Chin Med J (Engl). 2013;126(24):4736-4741.
77. Horváth Z, Kovalszky I, Fullár A, et al. Decorin deficiency promotes hepatic carcinogenesis. Matrix Biol. 2014;35:194-205.
78. Jim Leu SJ, Sung JS, Chen MY, et al. The matricellular protein CCN1 suppresses lung cancer cell growth by inducing senescence via the p53/p21 pathway. J Cell Biochem. 2013;114(9):2082-2093.
79. Nadir Y, Brenner B. Heparanase multiple effects in cancer. Thromb Res. 2014;133 Suppl 2:90-94.
80. Zhao H, Liu H, Chen Y, et al. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res. 2006;66(17):8779-8787.
81. Ishida K, Hirai G, Murakami K, et al. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. Mol Cancer Ther. 2004;3(9):1069-1077.
82. Tímár J, Diczházi C, Bartha I, et al. Modulation of heparan-sulphate/chondroitin-sulphate ratio by glycosaminoglycan biosynthesis inhibitors affects liver metastatic potential of tumor cells. Int J Cancer. 1995;62(6):755-761.
83. Pogány G, Jeney A, Timár J, Major J, Lapis K. Modulation of glycoconjugate biosynthesis by 5-hexyl-2′-deoxyuridine in highly metastatic Lewis lung carcinoma cells. Neoplasma. 1990;37(5):501-510.
84. Jeney A, Timár J, Pogány G, et al. Glycosaminoglycans as novel target in antitumor therapy. Tokai J Exp Clin Med. 1990;15(2-3):167-177.
85. Park CP, Bissel MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today. 2000;8:324-329.
86. Heino J, Massagué J. Transforming growth factor-beta switches the pattern of integrins expressed in MG-63 human osteosarcoma cells and causes a selective loss of cell adhesion to laminin. J Biol Chem. 1989;264(36):21806-21811.
87. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 1999;5(6):662-668.
88. Hayashido Y, Kitano H, Sakaue T, et al. Overexpression of integrin αv facilitates proliferation and invasion of oral squamous cell carcinoma cells via MEK/ERK signaling pathway that is activated by interaction of integrin αvβ8 with type I collagen. Int J Oncol. 2014;45(5):1875-1882.
89. Böger C, Warneke VS, Behrens HM, et al. Integrins αvβ 3 and α vβ 5 as prognostic, diagnostic, and therapeutic targets in gastric cancer. Gastric Cancer. Epub 2014 Oct 15.
90. Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 2007;6:11.
91. Ruffini F, Graziani G, Levati L, Tentori L, D'Atri S, Lacal PM. Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin. Int J Cancer. 2015;136(6):E45-E58.
92. Élez E, Kocáková I, Höhler T, et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015;26(1):132-140.
93. Zhou J, Chen Y, Lang JY, Lu JJ, Ding J. Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling. Mol Cancer Res. 2008;6(2):194-204.
94. Habibi D, Ogloff N, Jalili RB, et al. Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia. Invest New Drugs. 2012;30(4):1361-1370.
95. Williams TF, Mirando AC, Wilkinson B, Francklyn CS, Lounsbury KM. Secreted threonyl-tRNA synthetase stimulates endothelial cell migration and angiogenesis. Sci Rep. 2013;3:1317.
96. Bissell MJ, Weaver VM, Lelièvre SA, Wang F, Petersen OW, Schmeichel KL. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res. 1999;59(7 Suppl):1757s-1764s.
97. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonneoplastic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997;15(1):76-84.
98. Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol. 2001;12(2):89-98.
99. Kouniavsky G, Khaikin M, Zvibel I, et al. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clin Exp Metastasis. 2002;19(1):55-60.
100. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond). 2002;102(4):417-424.
101. Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011;47(16):2431-2445.
102. Fuks Z, Vlodavsky I, Andreeff M, McLoughlin M, Haimovitz-Friedman A. Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur J Cancer. 1992;28A(4-5):725-731.
103. Truong HH, Xiong J, Ghotra VP, et al. β1 integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer. Sci Signal. 2014;7(312):ra15.